65,437 trials
Skin Care
Primary: Percentage of Participants With Potential Sensitisation Reactions as Assessed by Dermatologist on Day 40 — 2; 1; 1; 0 Number of participants
Dental Pain
Primary: Area Under the Curve (AUC) of Numeric Rating Scale (NRS) Pain Intensity Scores Through 48 Hours — 178.9; 181.6 units on NRS scale*hr — p=0.8661
Nonsynostotic Plagiocephaly
Primary: Number of Participants With Qualitatively Determined Normalization of White Matter Pathways — 2 Participants
Faecal Incontinence
Primary: Opening Pressure — 35.13; 37.5 cmH2O
Healthy
Primary: Change in 17-OH Pregnenolone — 120; 158; 171; 170 ng/dl — p=>0.8
Rotavirus
Primary: Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations — 90.25; 94.16 U/mL
Hepatitis B Virus
Primary: Pharmacokinetic (PK) Parameter: AUCinf of Tenofovir Alafenamide (TAF), Its Metabolite Tenofovir (TFV) and Free (Unbound) TAF — 120.6; 228.2; 219.9; 304.0 h*ng/mL
Pancreatic Cancer
Primary: Procedure Duration Required for Placing the Fiducial Markers — 16; 9 mintues
Small Cell Lung Cancer
Primary: Overall Survival (OS) — 6.9; 7.0; 7.4 months
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Primary: The Percentage of Evaluable Participants With at Least One Confirmed Seizure as Adjudicated by the Independent Adjudication Committee (IAC) — 1.1 percentage of…
Prostate Cancer
Primary: Median Radiographic Progression Free Survival (PFS) — 16.8; 16.6 months
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-906 — 14.37; 89.62 nanogram per milliliter (ng/mL)
Posterolateral Thoracotomy · Postoperative Pain
Primary: Area Under the Curve (AUC) of Pain Intensity at Rest Through 72 Hours — 472.1; 459.0 score on a scale * hr — p=0.5598
Dry Eye Syndrome
Primary: Change of Baseline Tear Breakup Time (TBUT) — 0.75; 1.99 seconds
Rosacea
Primary: Percent Change (Reduction) of Lesion Count From Day 1 — 61.14; 57.27; 49.43 percentage of lesion reduction